Last reviewed · How we verify

Fenofibrate 200mg

Xijing Hospital of Digestive Diseases · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Fenofibrate 200mg is a Small molecule drug developed by Xijing Hospital of Digestive Diseases. It is currently FDA-approved. Also known as: Fibrate, Fenofibrate group.

Fenofibrate 200mg is a small molecule that acts as a peroxisome proliferator-activated receptor alpha agonist. It is used to treat conditions such as Primary Biliary Cholangitis, Hyperlipoproteinemia, and Severe Hypertriglyceridemia During Pregnancy.

At a glance

Generic nameFenofibrate 200mg
Also known asFibrate, Fenofibrate group
SponsorXijing Hospital of Digestive Diseases
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fenofibrate 200mg

What is Fenofibrate 200mg?

Fenofibrate 200mg is a Small molecule drug developed by Xijing Hospital of Digestive Diseases.

Who makes Fenofibrate 200mg?

Fenofibrate 200mg is developed and marketed by Xijing Hospital of Digestive Diseases (see full Xijing Hospital of Digestive Diseases pipeline at /company/xijing-hospital-of-digestive-diseases).

Is Fenofibrate 200mg also known as anything else?

Fenofibrate 200mg is also known as Fibrate, Fenofibrate group.

What development phase is Fenofibrate 200mg in?

Fenofibrate 200mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing